Genetic modification with the addition of the extracellular domains of PD-1 and CD137L (4-1BBL) led to a 70% long-term cure rate in a sub-cutaneous hepatocellular carcinoma (HCC) model (69). The gene discussed is TNFSF9; the disease is hepatocellular carcinoma.